カレントテラピー　31-4　サンプル page 23/30

このページは カレントテラピー　31-4　サンプル の電子ブックに掲載されている23ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
patients with atrial fibrillation. N Engl J Med 361：1139 -1151, 20094）Connolly SJ, Ezekowitz MD, Yusuf S, et al；RandomizedEvaluation of Long - Term Anticoagulation TherapyInvestigators：Newly ident....

patients with atrial fibrillation. N Engl J Med 361：1139 -1151, 20094）Connolly SJ, Ezekowitz MD, Yusuf S, et al；RandomizedEvaluation of Long - Term Anticoagulation TherapyInvestigators：Newly identified events in the RE-LY trial. NEngl J Med 363：1875-1876, 20105）Eikelboom JW, Wallentin L, Connolly SJ, et al：Risk of bleedingwith 2 doses of dabigatran compared with warfarin inolder and younger patients with atrial fibrillation：an analysisof the randomized evaluation of long -term anticoagulanttherapy RE -LY trial. Circulation 123：2363-2372, 20116）H o r i M , C o n n o l l y S J , E z e k o w i t z M D , e t a l；R E - L YInvestigators：Efficacy and safety of dabigatran vs. warfarinin patients with atrial fibrillation -sub -analysis in Japanesepopulation in RE-LY trial. Circ J 75：800-805, 20117）Elodi S, Varadi K：Optimization of conditions for the catalyticeffect of the factorⅨa-factorⅧcomplex：probable roleof the complex in the amplification of blood coagulation.Thromb Res 15：617-629, 19798）Samama MM：The mechanism of action of rivaroxaban- -anoral, direct factor Xa inhibitor- -compared with other anticoagulants.Thromb Res 127：497-504, 20119）Ansell J：Factor Xa or thrombin：is factor Xa a better target?J Thromb Haemost 5（Suppl 1）：60-64, 200710）Turpie AG：Oral, direct factor Xa inhibitors in developmentfor the prevention and treatment of thromboembolic diseases.Arterioscler Thromb Vasc Biol 27：1238 -1247, 200711）Wong PC, Crain EJ, Watson CA, et al：Favorable therapeuticindex of the direct factor Xa inhibitors, apixaban and rivaroxaban,compared with the thrombin inhibitor dabigatran inrabbits. J Thromb Haemost 7：1313 -1320, 200912）Cohen AT, Spiro TE, Buller HR, et al：Extended-duration rivaroxabanthromboprophylaxis in acutely ill medical patients：MAGELLAN study protocol. J Thromb Thrombolysis 31：407-416, 201113）Patel MR, Mahaffey KW, Garg J, et al；ROCKET AFInvestigators：Rivaroxaban versus warfarin in nonvalvularatrial fibrillation. N Engl J Med 365：883 -891, 201114）Hori M, Matsumoto M, Tanahashi N, et al；J -ROCKET AFstudy investigators：Rivaroxaban vs. warfarin in Japanesepatients with atrial fibrillation -the J -ROCKET AF study -.Circ J 76：2104-2111, 201215）Eikelboom JW, Weitz JI：New anticoagulants. Circulation121：1523 -1532, 201016）Garcia D, Libby E, Crowther MA：The new oral anticoagulants.Blood 115：15-20, 201017）G r a n g e r C B , A l e x a n d e r J H , M c M u r r a y J J , e t a l；ARISTOTLE Committees and Investigators：Apixaban versuswarfarin in patients with atrial fibrillation. N Engl J Med365：981 -992, 201182Current Therapy 2013 Vol.31 No.4430